Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.

Pauthner M, Yeung J, Ullman C, Bakker J, Wurch T, Reichert JM, Lund-Johansen F, Bradbury AR, Carter PJ, Melis JP.

MAbs. 2016;8(3):617-52. doi: 10.1080/19420862.2016.1153211.

2.

9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.

Reichert JM, Beck A, Lugovskoy AA, Wurch T, Coats S, Brezski RJ.

MAbs. 2014 Mar-Apr;6(2):309-26. doi: 10.4161/mabs.27903. Epub 2014 Jan 17.

PMID:
24492298
3.

8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.

Beck A, Carter PJ, Gerber HP, Lugovskoy AA, Wurch T, Junutula JR, Kontermann RE, Mabry R.

MAbs. 2013 May-Jun;5(3):339-57. doi: 10.4161/mabs.24105. Epub 2013 Mar 14.

4.

Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept.

Wurch T, Pierré A, Depil S.

Trends Biotechnol. 2012 Nov;30(11):575-82. doi: 10.1016/j.tibtech.2012.07.006. Epub 2012 Sep 1. Review.

PMID:
22944617
5.

IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Nilvebrant J, Dunlop DC, Sircar A, Wurch T, Falkowska E, Reichert JM, Helguera G, Piccione EC, Brack S, Berger S.

MAbs. 2012 Mar-Apr;4(2):153-81. doi: 10.4161/mabs.4.2.19495. Epub 2012 Mar 1.

6.

6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Beck A, Wurch T, Reichert JM.

MAbs. 2011 Mar-Apr;3(2):111-32. Epub 2011 Mar 1.

7.
8.

The next generation of antibody-drug conjugates comes of age.

Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N.

Discov Med. 2010 Oct;10(53):329-39. Review.

9.

Strategies and challenges for the next generation of therapeutic antibodies.

Beck A, Wurch T, Bailly C, Corvaia N.

Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747. Review.

PMID:
20414207
10.

5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Beck A, Reichert JM, Wurch T.

MAbs. 2010 Mar-Apr;2(2):108-28. No abstract available.

11.

Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.

Wurch T, Larbouret C, Robert B.

MAbs. 2009 Jul-Aug;1(4):318-25. Epub 2009 Jul 28.

12.

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.

Beck A, Cochet O, Wurch T.

Expert Opin Drug Discov. 2010 Jan;5(1):95-111. doi: 10.1517/17460440903413504. Epub 2009 Dec 1.

PMID:
22823974
13.

[Protein scaffolds as alternatives to whole antibodies: from discovery research to clinical development].

Wurch T, Lowe P, Beck A, Corvaia N.

Med Sci (Paris). 2009 Dec;25(12):1169-72. doi: 10.1051/medsci/200925121169. Review. French.

14.

[Therapeutic antibodies and related products: choosing the right structure for success].

Beck A, Wagner-Rousset E, Wurch T, Corvaia N.

Med Sci (Paris). 2009 Dec;25(12):1024-32. doi: 10.1051/medsci/200925121024. Review. French.

15.

Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation.

Wurch T, Lowe P, Caussanel V, Bes C, Beck A, Corvaia N.

Curr Pharm Biotechnol. 2008 Dec;9(6):502-9. Review.

PMID:
19075688
16.

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.

Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, Goetsch L, Wurch T, Van Dorsselaer A, Corvaïa N.

Curr Pharm Biotechnol. 2008 Dec;9(6):482-501. Review.

PMID:
19075687
17.

Therapeutic antibodies and derivatives: from the bench to the clinic.

Beck A, Wurch T, Corvaïa N.

Curr Pharm Biotechnol. 2008 Dec;9(6):421-2. No abstract available.

PMID:
19075681
18.

Peptides as tools and drugs for immunotherapies.

Beck A, Klinguer-Hamour C, Bussat MC, Champion T, Haeuw JF, Goetsch L, Wurch T, Sugawara M, Milon A, Van Dorsselaer A, Nguyen T, Corvaïa N.

J Pept Sci. 2007 Sep;13(9):588-602. Review.

PMID:
17602441
19.
20.

Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling.

Heusler P, Pauwels PJ, Wurch T, Newman-Tancredi A, Tytgat J, Colpaert FC, Cussac D.

Neuropharmacology. 2005 Dec;49(7):963-76. Epub 2005 Jun 17.

PMID:
15964603
21.

Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands.

Rival Y, Stennevin A, Puech L, Rouquette A, Cathala C, Lestienne F, Dupont-Passelaigue E, Patoiseau JF, Wurch T, Junquéro D.

J Pharmacol Exp Ther. 2004 Nov;311(2):467-75. Epub 2004 Jul 23.

PMID:
15273253
22.

Modulation of 5-HT(1A) receptor-mediated Ca(2+) responses by co-expression with various recombinant G(alpha) proteins in CHO-K1 cells.

Wurch T, Pauwels PJ.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Aug;368(2):99-105. Epub 2003 Jul 16.

PMID:
12879209
23.

Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells.

Gazi L, Wurch T, Lopéz-Giménez JF, Pauwels PJ, Strange PG.

FEBS Lett. 2003 Jun 19;545(2-3):155-60.

26.

Endogenous RGS proteins facilitate dopamine D(2S) receptor coupling to G(alphao) proteins and Ca2+ responses in CHO-K1 cells.

Boutet-Robinet EA, Finana F, Wurch T, Pauwels PJ, De Vries L.

FEBS Lett. 2003 Jan 2;533(1-3):67-71.

27.

Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.

Wurch T, Boutet-Robinet EA, Palmier C, Colpaert FC, Pauwels PJ.

J Pharmacol Exp Ther. 2003 Jan;304(1):380-90.

PMID:
12490615
28.

Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by co-expression with different G alpha protein subunits.

Pauwels PJ, Rauly I, Wurch T, Colpaert FC.

Neuropharmacology. 2002 May;42(6):855-63.

PMID:
12015212
29.

Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor.

Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR.

Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33.

PMID:
11834243
30.

Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor.

Wurch T, Junquero D, Delhon A, Pauwels J.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):133-40. Epub 2001 Nov 23.

PMID:
11819031
31.
33.
34.
35.

Molecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT(1B) receptor.

Bhalla P, Sharma HS, Ma X, Wurch T, Pauwels PJ, Saxena PR.

Br J Pharmacol. 2001 Jul;133(6):891-901.

36.

Different regulation of RGS2 mRNA by haloperidol and clozapine.

Robinet EA, Wurch T, Pauwels PJ.

Neuroreport. 2001 Jun 13;12(8):1731-5.

PMID:
11409749
37.

Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.

Pauwels PJ, Wurch T, Tardif S, Finana F, Colpaert FC.

Naunyn Schmiedebergs Arch Pharmacol. 2001 May;363(5):526-36.

PMID:
11383713
38.

Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.

Pauwels PJ, Tardif S, Colpaert FC, Wurch T.

Biochem Pharmacol. 2001 May 1;61(9):1079-92.

PMID:
11301041
39.

Dynamic dopamine-antagonist interactions at recombinant human dopamine D(2short) receptor: dopamine-bound versus antagonist-bound receptor states.

Pauwels PJ, Finana F, Tardif S, Wurch T, Colpaert FC.

J Pharmacol Exp Ther. 2001 Apr;297(1):133-40.

PMID:
11259537
40.

Modulation of 5-HT(1A) receptor activation by its interaction with wild-type and mutant g(alphai3) proteins.

Dupuis DS, Wurch T, Tardif S, Colpaert FC, Pauwels PJ.

Neuropharmacology. 2001;40(1):36-47.

PMID:
11077069
41.

Molecular cloning, sequence analysis and pharmacological properties of the porcine 5-HT(1D) receptor.

Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR.

Br J Pharmacol. 2000 Nov;131(5):949-57.

42.

New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.

Mayer P, Brunel P, Chaplain C, Piedecoq C, Calmel F, Schambel P, Chopin P, Wurch T, Pauwels PJ, Marien M, Vidaluc JL, Imbert T.

J Med Chem. 2000 Oct 5;43(20):3653-64.

PMID:
11020279
44.

Agonist efficacy at the alpha2A-adrenoceptor:G alpha15 fusion protein: an analysis based on Ca2+ responses.

Pauwels PJ, Finana F, Tardif S, Colpaert FC, Wurch T.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Jun;361(6):672-9.

PMID:
10882043
45.

alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway.

Rauly I, Ailhaud M, Wurch T, Pauwels PJ.

Biochem Pharmacol. 2000 Jun 15;59(12):1531-8.

PMID:
10799649
46.
48.

Ligand-receptor interactions as controlled by wild-type and mutant Thr(370)Lys alpha2B-adrenoceptor-Galpha15 fusion proteins.

Pauwels PJ, Tardif S, Finana F, Wurch T, Colpaert FC.

J Neurochem. 2000 Jan;74(1):375-84.

50.

Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein.

Dupuis DS, Tardif S, Wurch T, Colpaert FC, Pauwels PJ.

Neuropharmacology. 1999 Jul;38(7):1035-41.

PMID:
10428422

Supplemental Content

Support Center